Castle Biosciences Inc
NASDAQ:CSTL
Income Statement
Earnings Waterfall
Castle Biosciences Inc
Revenue
|
219.8m
USD
|
Cost of Revenue
|
-45m
USD
|
Gross Profit
|
174.8m
USD
|
Operating Expenses
|
-242.8m
USD
|
Operating Income
|
-68m
USD
|
Other Expenses
|
10.5m
USD
|
Net Income
|
-57.5m
USD
|
Income Statement
Castle Biosciences Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
23
N/A
|
28
+22%
|
35
+24%
|
46
+32%
|
52
+14%
|
61
+17%
|
63
+3%
|
63
+1%
|
63
-1%
|
68
+9%
|
78
+15%
|
86
+11%
|
94
+9%
|
98
+4%
|
110
+12%
|
124
+12%
|
137
+11%
|
152
+11%
|
168
+10%
|
192
+15%
|
220
+14%
|
|
Gross Profit | ||||||||||||||||||||||
Cost of Revenue |
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(9)
|
(10)
|
(10)
|
(12)
|
(14)
|
(16)
|
(19)
|
(23)
|
(27)
|
(32)
|
(36)
|
(40)
|
(42)
|
(45)
|
|
Gross Profit |
18
N/A
|
22
+27%
|
28
+27%
|
39
+38%
|
45
+14%
|
52
+18%
|
54
+3%
|
54
-1%
|
53
-2%
|
58
+9%
|
66
+15%
|
72
+9%
|
78
+8%
|
79
+1%
|
87
+10%
|
97
+10%
|
105
+9%
|
116
+10%
|
128
+10%
|
150
+17%
|
175
+17%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(21)
|
(23)
|
(26)
|
(30)
|
(37)
|
(39)
|
(42)
|
(55)
|
(60)
|
(71)
|
(88)
|
(102)
|
(118)
|
(137)
|
(161)
|
(180)
|
(196)
|
(217)
|
(225)
|
(235)
|
(243)
|
|
Selling, General & Administrative |
(16)
|
(18)
|
(21)
|
(24)
|
(30)
|
(35)
|
(38)
|
(43)
|
(48)
|
(55)
|
(65)
|
(76)
|
(86)
|
(98)
|
(115)
|
(129)
|
(142)
|
(158)
|
(165)
|
(173)
|
(179)
|
|
Research & Development |
(5)
|
(5)
|
(5)
|
(5)
|
(7)
|
(9)
|
(10)
|
(12)
|
(13)
|
(16)
|
(20)
|
(25)
|
(29)
|
(34)
|
(39)
|
(43)
|
(45)
|
(48)
|
(50)
|
(52)
|
(53)
|
|
Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(3)
|
(5)
|
(7)
|
(8)
|
(10)
|
(10)
|
(10)
|
(11)
|
(11)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
5
|
7
|
0
|
2
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(4)
N/A
|
(1)
+72%
|
2
N/A
|
9
+329%
|
7
-23%
|
14
+90%
|
13
-9%
|
(1)
N/A
|
(7)
-622%
|
(13)
-104%
|
(21)
-62%
|
(29)
-37%
|
(40)
-37%
|
(58)
-44%
|
(73)
-27%
|
(83)
-13%
|
(91)
-10%
|
(101)
-10%
|
(98)
+3%
|
(85)
+12%
|
(68)
+20%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(2)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(3)
|
(2)
|
(2)
|
(2)
|
(1)
|
(0)
|
0
|
(2)
|
18
|
20
|
22
|
27
|
9
|
10
|
11
|
|
Non-Reccuring Items |
0
|
0
|
0
|
5
|
5
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
(1)
|
(3)
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(6)
N/A
|
(4)
+36%
|
(2)
+46%
|
7
N/A
|
5
-25%
|
7
+37%
|
7
-2%
|
(3)
N/A
|
(10)
-212%
|
(15)
-48%
|
(22)
-49%
|
(30)
-32%
|
(40)
-35%
|
(60)
-51%
|
(55)
+9%
|
(64)
-15%
|
(69)
-8%
|
(74)
-7%
|
(89)
-21%
|
(75)
+15%
|
(57)
+24%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
9
|
9
|
11
|
11
|
2
|
2
|
(0)
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(6)
|
(4)
|
(2)
|
7
|
5
|
7
|
7
|
(3)
|
(10)
|
(15)
|
(23)
|
(30)
|
(31)
|
(52)
|
(44)
|
(53)
|
(67)
|
(72)
|
(89)
|
(76)
|
(57)
|
|
Net Income (Common) |
(10)
N/A
|
(8)
+21%
|
(6)
+23%
|
4
N/A
|
3
-21%
|
6
+97%
|
7
+15%
|
(3)
N/A
|
(10)
-208%
|
(15)
-47%
|
(23)
-49%
|
(30)
-32%
|
(31)
-5%
|
(52)
-65%
|
(44)
+14%
|
(53)
-19%
|
(67)
-27%
|
(72)
-7%
|
(89)
-24%
|
(76)
+15%
|
(57)
+24%
|
|
EPS (Diluted) |
-0.63
N/A
|
-0.5
+21%
|
-0.39
+22%
|
0.21
N/A
|
0.17
-19%
|
0.33
+94%
|
0.39
+18%
|
-0.16
N/A
|
-0.54
-238%
|
-0.6
-11%
|
-0.89
-48%
|
-1.17
-31%
|
-1.24
-6%
|
-2.04
-65%
|
-1.7
+17%
|
-2.01
-18%
|
-2.58
-28%
|
-2.71
-5%
|
-3.32
-23%
|
-2.81
+15%
|
-2.14
+24%
|